Sugi Predict

Sugi Predict / Compounds / SCHEMBL555425

SCHEMBL555425

SCHEMBL555425

Cc1ccccc1OC(C(=O)O)(c1ccccc1C)C(O)C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.36
▸ RXRA P19793 1/20 0.35
▸ RXRB P28702 1/20 0.35
▸ RXRG P48443 1/20 0.35
▸ NOTUM Q6P988 1/20 0.35
▸ HTT P42858 2/20 0.35
▸ CASP1 P29466 1/20 0.34
▸ TDP1 Q9NUW8 3/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ GAA P10253 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ PPARG P37231 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1162260 1.00 KDM4E (0.38) KDM4ECYP1A2ALDH1A1RXRARXRB
SCHEMBL4668126 1.00 KDM4E (0.38) KDM4ECYP1A2ALDH1A1RXRARXRB
SCHEMBL4214182 0.78 HPGD (0.38) KDM4EALDH1A1TDP1SMN1; SMN2GAA
SCHEMBL8188892 0.77 NOTUM (0.36) CYP1A2NOTUMTDP1SMN1; SMN2PPARG
Water SCHEMBL8734708 0.76 NOTUM (0.35) CYP1A2NOTUMTDP1SMN1; SMN2PPARG
SCHEMBL5310850 0.73 ATM (0.38) KDM4ECYP1A2ALDH1A1RXRARXRB
SCHEMBL697581 0.72 CPT2 (0.35) KDM4ECYP1A2ALDH1A1TDP1GAA
SCHEMBL12817104 0.72 CPT2 (0.35) KDM4ECYP1A2ALDH1A1TDP1GAA
Water SCHEMBL28155256 0.71 CPT2 (0.34) KDM4ECYP1A2ALDH1A1TDP1GAA
SCHEMBL31070064 0.71 EDNRB (0.37) SMN1; SMN2GAAL3MBTL1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 660 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117946102-A Non-nefardone diastereomer salt and method for preparing non-nefardone by using same 江苏德源药业股份有限公司 2024-04-30 — — CN claimed
CN-118420658-B Preparation method of chiral triazine compound 天津辰欣药物研究有限公司 2024-09-20 — — CN disclosed
CN-118420658-A Preparation method of chiral triazine compound 天津辰欣药物研究有限公司 2024-08-02 — — CN disclosed
CN-117946102-A Non-nefardone diastereomer salt and method for preparing non-nefardone by using same 江苏德源药业股份有限公司 2024-04-30 — — CN disclosed
EP-3517539-B1 SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, ITS PREPARATION AND ITS USE IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TYPE I AND II DIABETES BOEHRINGER INGELHEIM INT (DE) 2022-12-14 — — EP disclosed
EP-3527573-B9 SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS GILEAD SCIENCES INC (US) 2022-07-06 — — EP disclosed
US-10975096-B2 Synthesis of polycyclic-carbamoylpyridone compounds GILEAD SCIENCES, INC. (US) 2021-04-13 — — US disclosed
EP-3783001-A1 SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS Gilead Sciences, Inc. (US) 2021-02-24 — — EP disclosed
EP-3527573-B1 SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS GILEAD SCIENCES INC (US) 2020-08-12 — — EP disclosed
US-20200223866-A1 SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS GILEAD SCIENCES, INC. 2020-07-16 — — US disclosed
US-3980657-A FIBRINOLYTICS, THROMBOLYTICS, ANTIPHLOGISTICS, ANALGESICS CIBA-GEIGY CORPORATION (US) 1976-09-14 — — US disclosed
US-3978041-A CARDIAC INSUFFICIENCY CIBA-GEIGY CORPORATION (US) 1976-08-31 — — US disclosed
US-3976778-A ANTHELMINTIC, BACTERICIDE, ANTIPROTOZOA CIBA-GEIGY CORPORATION (US) 1976-08-24 — — US disclosed
US-3974280-A Benzothiophenes CIBA-GEIGY CORPORATION (US) 1976-08-10 — — US disclosed
US-3973024-A Analgesic and anti-inflammatory anilino-phenylacetic acid-(2,3 or 4 pyridyl)-methyl esters and derivatives CIBA-GEIGY CORPORATION (US) 1976-08-03 — — US disclosed
US-3956335-A HYPERTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1976-05-11 — — US disclosed
US-3949088-A Substituted phenoxy propanol amines used for treating cardiovascular diseases SAMUELSSON BENNY ROGER 1976-04-06 — — US disclosed
US-3944589-A α-Cycloalkenylphenyl-fatty acid nitriles CIBA-GEIGY CORPORATION (US) 1976-03-16 — — US disclosed
US-3935259-A 2-HYDROXY-3-(UREIDOPHENOXY)PROPYL, CARDIAC BETA RECEPTOR INHIBITORS CIBA-GEIGY CORPORATION (US) 1976-01-27 — — US disclosed
US-3933802-A New sulphamoylbenzoic acid amides CIBA-GEIGY CORPORATION (US) 1976-01-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200223866-A1 SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS CPS1, SDHA, DHPS KDM4E 1101/4885CYP1A2 198/4885ALDH1A1 883/4885
US-10975096-B2 Synthesis of polycyclic-carbamoylpyridone compounds CPS1, SDHA, DHPS KDM4E 1101/4885CYP1A2 198/4885ALDH1A1 883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.